CytoDyn Appoints Mahboob Rahman, M.D., Ph.D., as Chief Scientific Officer - Seite 2
While working in the pharmaceutical industry, Dr. Rahman maintained his educational and clinical activities. He was an adjunct Professor at University of Pennsylvania School of Medicine from 2002 to 2016 and a Clinical Professor at the Rutgers RWJ School of Medicine, Rheumatology Division, from 2016 to 2018. He has published more than 100 scientific papers in peer-reviewed journals.
Scott A. Kelly, M.D., Chairman of the Board, Chief Medical Officer and Head of Business Development for CytoDyn, stated, “We are very pleased Dr. Rahman has joined our executive team. We expect his deep knowledge of immunology and successful regulatory experience to prove invaluable for patients and our Company.”
Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, commented, “We believe Dr. Rahman’s proven track record in our industry, coupled with his medical and research expertise will undoubtedly help accelerate many of our clinical and regulatory priorities. With the addition of Dr. Rahman, along with Dr. Scott Kelly, our CMO, and Dr. Nitya Ray, our CTO, we believe we are well-positioned to move CytoDyn into its next phase of development.”
CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.
CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. The FDA met telephonically with Company key personnel and its clinical research organization and provided written responses to the Company’s questions concerning its recent Biologics License Application (“BLA”) for this HIV combination therapy in order to expedite the resubmission of its BLA filing for this indication.
CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than six years.